A detailed history of Tower Research Capital LLC (Trc) transactions in Tenaya Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 5,264 shares of TNYA stock, worth $8,790. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,264
Previous 15,594 66.24%
Holding current value
$8,790
Previous $48,000 79.17%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.93 - $3.99 $19,936 - $41,216
-10,330 Reduced 66.24%
5,264 $10,000
Q2 2024

Aug 13, 2024

BUY
$2.72 - $4.99 $36,301 - $66,596
13,346 Added 593.68%
15,594 $48,000
Q1 2024

May 15, 2024

SELL
$2.88 - $6.8 $8,858 - $20,916
-3,076 Reduced 57.78%
2,248 $11,000
Q4 2023

Feb 13, 2024

SELL
$1.73 - $3.39 $13,090 - $25,652
-7,567 Reduced 58.7%
5,324 $17,000
Q3 2023

Nov 14, 2023

BUY
$2.55 - $5.65 $20,364 - $45,120
7,986 Added 162.81%
12,891 $32,000
Q2 2023

Aug 14, 2023

BUY
$2.64 - $7.64 $6,320 - $18,290
2,394 Added 95.34%
4,905 $28,000
Q1 2023

May 09, 2023

SELL
$1.92 - $3.59 $7,121 - $13,315
-3,709 Reduced 59.63%
2,511 $7,000
Q4 2022

Feb 10, 2023

SELL
$1.68 - $3.19 $2,892 - $5,493
-1,722 Reduced 21.68%
6,220 $12,000
Q3 2022

Nov 10, 2022

BUY
$2.9 - $5.88 $15,080 - $30,576
5,200 Added 189.64%
7,942 $23,000
Q2 2022

Aug 15, 2022

BUY
$5.01 - $14.12 $8,787 - $24,766
1,754 Added 177.53%
2,742 $15,000
Q1 2022

May 12, 2022

SELL
$9.41 - $19.3 $10,877 - $22,310
-1,156 Reduced 53.92%
988 $12,000
Q4 2021

Feb 14, 2022

BUY
$18.41 - $29.58 $30,652 - $49,250
1,665 Added 347.6%
2,144 $41,000
Q3 2021

Nov 15, 2021

BUY
$15.35 - $26.66 $7,352 - $12,770
479 New
479 $10,000

Others Institutions Holding TNYA

About Tenaya Therapeutics, Inc.


  • Ticker TNYA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,364,700
  • Market Cap $69.1M
  • Description
  • Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hyp...
More about TNYA
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.